Tianshui Zhongxing Bio-technology 众兴菌业
4 significant filings since 30 May 2026: 1 on share pledge, 1 on guarantee or financial assistance and 1 on equity incentive, and 1 other kind. The latest, on 5 Sep 2026: 关于调剂担保额度及对外担保进展公告. On 15 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 160.79% to 189.77% from the same period a year earlier.
自 30 May 2026 起有 4 份重大公告：share pledge 1 份、guarantee or financial assistance 1 份、equity incentive 1 份，另有 1 类。最新一份（5 Sep 2026）：关于调剂担保额度及对外担保进展公告。15 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 160.79% 至 189.77%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 太平洋 | 程晓东 | Buy 买入 | 24 Aug 2026 | 1 | — |
| 西南证券 | 徐卿,赵磐 | Buy 买入 | 18 Aug 2026 | 6 | — |
| 东兴证券 | 孟斯硕,王洁婷 | Outperform 增持 | 28 Jul 2026 | 1 | — |
| 东吴证券 | 苏铖,李茵琦 | Buy 买入 | 2 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 1 of 9 reports. 每行为该券商近十二个月的最新研报；9 份中 1 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。